{"id":"W4387807145","doi":"10.1016/j.annonc.2023.09.1020","title":"2371P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Gilead Sciences; Pfizer","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Internal medicine; Clinical endpoint; Progression-free survival; Adverse effect; Maintenance therapy; Chemotherapy; Oncology; Surgery; Urology; Randomized controlled trial; Urothelial carcinoma; Bladder cancer; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001130627,0.0005435417,0.001386575,0.000191516,0.0002175838,0.001062051,0.0003944658,0.0005794496,0.001696609],"category_scores_gemma":[0.0009681816,0.0002237959,0.001535533,0.0003951395,0.0004305581,0.0008437764,0.0004114884,0.001903109,0.000337624],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006134625,"about_ca_system_score_gemma":0.0005201121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001181949,"about_ca_topic_score_gemma":0.002935875,"domain_scores_codex":[0.9996701,0.0001317279,0.00001930058,0.00006442062,0.00003136743,0.00008309802],"domain_scores_gemma":[0.9995002,0.000086969,0.0001440576,0.00004075526,0.00002489006,0.0002032001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.736838,0.005591802,0.07083125,0.001914926,0.007992516,0.0003654621,0.000287124,0.003066558,0.01177058,0.0004882191,0.01006419,0.1507894],"study_design_scores_gemma":[0.3662016,0.1758888,0.4232702,0.0005012213,0.0114183,0.001024195,0.0004491445,0.00385328,0.002822818,0.001092676,0.01331586,0.0001619968],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925265,0.004820569,0.00009397668,0.0004111858,0.0001055736,0.00007875083,0.001033842,0.00002033674,0.0009092234],"genre_scores_gemma":[0.9926577,0.00282594,0.0001851051,0.0005847948,0.0001604716,0.000117323,0.002341631,0.00001063044,0.001116378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001696609,"threshold_uncertainty_score":0.005979419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1013763211498308,"score_gpt":0.3908617117349309,"score_spread":0.2894853905851001,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}